Retinal Drugs Market by Distribution Channel, Indication, and Geography - Forecast and Analysis 2023-2027

Published: Jan 2023 Pages: 167 SKU: IRTNTR70326

Retinal Drugs Market Analysis Report 2023-2027: 

The retinal drugs market size is estimated to grow at a CAGR of 6.27% between 2022 and 2027. The retinal drugs market size is forecast to increase by USD 7,275.79 million. The growth of the market depends on several factors, including the rise in the prevalence of retinal diseases, the emergence of advanced diagnostic tools, and patient assistance programs. 

This retinal drugs market report extensively covers market segmentation by distribution channel (hospital pharmacy, retail pharmacy, and online pharmacy), indication (macular degeneration, diabetic eye disease, and others), and geography (North America, Europe, Asia, and Rest of World (ROW). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

What will be the size of the Retinal Drugs Market During the Forecast Period?

To learn more about this report, Download Report Sample

Retinal Drugs Market: Key Drivers, Trends, Challenges, and Customer Landscape

The rise in the prevalence of retinal diseases is notably driving the market growth, although factors such as limitations and risk factors associated with current retinal disease treatment drugs may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Retinal Drugs Market Driver

The rise in the prevalence of retinal diseases is notably driving the market growth. The prevalence of retinal diseases such as wet AMD, diabetic retinopathy, DME, RVO, and mCNV is significantly increasing in developed and developing countries. AMD is the leading cause of visual disability in industrialized countries and the third leading cause of visual disability worldwide. It is expected that 202,200 million will suffer from AMD globally. Nearly nine out of every ten cases of AMD-related severe vision loss results from wet AMD. Every year, about 500,000 individuals are newly diagnosed with wet AMD globally. 

The increasing prevalence of retinal diseases is associated with the rise in risk factors. RVO typically affects people over the age of 50 years, and the incidence increases with age. The risk of getting advanced AMD increases from 2% for people in the age group of 50-59 to nearly 30% for those over the age of 75. Globally, the older population is also growing rapidly owing to the rise in average life expectancy. By 2025, it is expected that approximately 810 million people will be aged 65 and above across the world. The increasing worldwide incidence of diabetes is also leading to an increase in the incidence of diabetic retinopathy, DME, and other complications. Therefore, these factors will increase the demand for retinal drugs, thereby, driving the market growth during the forecast period.

Significant Retinal Drugs Market Trends

The rise in demand for sustained-release ocular formulations is an emerging trend in the market. Although anti-VEGF treatments are effective in many patients, the route of administration and duration of treatment remain limitations to therapy. Sustained-release ocular formulations can address the limitations of many of the current delivery modalities by reducing dosing frequency, eliminating the need for patient-administered drugs, and bypassing the physical barriers of the ocular tissues. The ozurdex implant is an approved biological intravitreal sustained DDS, which can release dexamethasone over the course of several months, leading to a marked improvement in visual acuity.

The demand for new sustained-release ocular DDS is steadily increasing due to the growing prevalence of major eye diseases, increasing R&D to find new approaches to deliver therapeutics, including small and large molecules, and the increasing need to reduce the frequency burden of repeat intravitreal injections. Several vendors are also increasingly focusing on the development of sustained-release formulations for the treatment of various retinal diseases. Thus, the rise in demand for sustained-release ocular formulations is expected to drive the growth of the global market during the forecast period.

Major Retinal Drugs Market Challenge

The limitations and risk factors associated with current retinal disease treatment drugs are major challenges impeding market growth. Anti-VEGF drugs have been very successful in improving the visual outcomes of people with retinal disorders. However, they do not cure the underlying problem of these disorders. Despite being the most effective treatment for many retinal diseases, the visual improvement gained using anti-VEGF drugs is modest, averaging about two lines of vision and only a few regain their normal vision. The repeated and long-term use of anti-VEGF drugs is also associated with some systemic adverse events and devastating ocular complications, including serious infections, retinal detachment, cataracts, and glaucoma. There is also a potential risk of blood clots leading to a heart attack or a stroke. In addition, VEGF is an essential factor for cell survival, and the sustained blocking of VEGF can lead to undesirable adverse effects such as chorioretinal atrophy and cardiovascular complications.

Similarly, Avastin, which is widely prescribed to patients with retinal disorders, is also associated with several limitations and drawbacks. The lack of regulatory oversight has led to the widespread circulation of foreign counterfeit bevacizumab in several US medical practices. Also, systemic bevacizumab must be converted into ophthalmic form through a compounding process performed by local pharmacies. Any contamination introduced during the compounding of bevacizumab for ophthalmic use increases the risk of post-injection endophthalmitis. Bevacizumab from compounding pharmacies may contain drug concentrations lower than those used in clinical trials supporting bevacizumab efficacy. Such concerns may deter physicians from prescribing Avastin despite its clinical and financial advantages. Hence, such limitations will hinder the global market growth during the forecast period.

Key Retinal Drugs Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Retinal Drugs Market Customer Landscape

Who are the Major Retinal Drugs Market Vendors?

Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

AbbVie Inc. -  The company conducts research and development, manufacturing, commercialization, and sale of innovative medicines and therapies to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. The key offerings of the company include retinal drugs. 

The retinal drugs market report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:

  • Bayer AG
  • Alcon Inc.
  • Alimera Sciences Inc.
  • Bausch Health Co Inc.
  • Bristol Myers Squibb Co.
  • F. Hoffmann La Roche Ltd.
  • Kubota Corp.
  • MeiraGTx Holdings Plc
  • Novartis AG
  • Ocular Therapeutix Inc.
  • Oxurion NV
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • REGENXBIO Inc
  • Sanofi SA

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

What is the Fastest-Growing Segment in the Retinal Drugs Market?

The market share growth by the hospital pharmacy segment will be significant during the forecast period. Hospital pharmacies comprise places selling drugs and other pharmaceutical-related products by hospitals from different pharmaceutical companies and are used for the treatment of either outpatients or inpatients.

Get a glance at the market contribution of various segments View a PDF Sample

The hospital pharmacy segment was valued at USD 10,380.76 million in 2017 and continued to grow until 2021. The drugs that are found in hospital pharmacies include therapeutic and critical care drugs. These drugs have applications in retinal diseases. The primary aim of hospital pharmacies is to procure, store, and sell medications to patients in hospitals. Hospital pharmaceuticals are administered to individuals during the hospital-enabled treatment period. They have rapidly emerged as the preferred distribution channel for compounded drugs. The reach and influence of hospitals will continue to increase as they purchase or take controlling stakes in physician practices. More hospitals are consolidating into larger healthcare systems, which can include payors, speciality services, outpatient clinics, long-term care facilities, and physician practices. Thus, owing to such factors the segment is expected to grow during the forecast period.

Which are the Key Regions for the Retinal Drugs Market?

For more insights on the market share of various regions Request PDF Sample now!

North America is estimated to contribute 42% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

North America accounts for the majority of the market share in the global market. The US is the major revenue generator in North America, followed by Canada. This is due to the high prevalence of retinal disorders and the high awareness among people about retinal disorders. Furthermore, Medicare provides coverage for all three anti-VEGF drugs, LUCENTIS, EYLEA, and Avastin, that are majorly prescribed for retinal disorders. The market in the US is expected to grow steadily due to the rising geriatric population and the related risk factors for retinal disorders. Furthermore, every year, approximately 1.5 million people in the region are diagnosed with diabetes. This is leading to an increase in the incidence of diabetic retinopathy, DME, and other complications. Thus, there is an increase in demand for retinal drugs, which, in turn, will drive market growth in the region during the forecast period.

The outbreak of COVID-19 negatively affected the market. However, following the widespread COVID-19 vaccination drives, lockdown restrictions in various countries were somewhat relaxed in 2021, which led to the resumption of business activities and manufacturing units of retinal drugs. Thus, such factors are expected to boost the growth of the market in North America during the forecast period.

Segment Overview

The retinal drugs market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

  • Distribution Channel Outlook (USD Million, 2017 - 2027)
    • Hospital pharmacy
    • Retail pharmacy
    • Online Pharmacy
  • Indication Outlook (USD Million, 2017 - 2027)
    • Macular degeneration
    • Diabetic eye disease
    • Others
  • Region Outlook (USD Million, 2017 - 2027)
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
      • Vietnam
      • Others
    • Rest of World
      • Saudi Arabia
      • South Africa
      • Brazil
      • Others

Retinal Drugs Market Scope

Report Coverage

Details

Page number

167

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 6.27%

Market growth 2023-2027

USD 7,275.79 million

Market structure

Fragmented

YoY growth 2022-2023(%)

5.67

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 42%

Key countries

US, Canada, Germany, Spain, and China

Competitive landscape

 Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

Bayer AG, AbbVie Inc., Alcon Inc., Alimera Sciences Inc., Bausch Health Co Inc., Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Kubota Corp., MeiraGTx Holdings Plc, Novartis AG, Ocular Therapeutix Inc., Oxurion NV, Pfizer Inc., Regeneron Pharmaceuticals Inc., REGENXBIO Inc, Sanofi SA, Santen Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Visufarma, and Johnson and Johnson Services Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Retinal Drugs Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the retinal drugs market between 2023 and 2027
  • Precise estimation of the size of the retinal drugs market size and its contribution to the parent market
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the industry across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information about vendors 
  • Comprehensive analysis of factors that will challenge the growth of retinal drugs market vendors

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Distribution Channel
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Indication
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global retinal drugs market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on Global retinal drugs market 2017 - 2021 ($ million)
    • 4.2 Ditribution channel Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Ditribution channel Segment 2017 - 2021 ($ million)
    • 4.3 Indication Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Indication Segment 2017 - 2021 ($ million)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Distribution Channel

    • 6.1 Market segments
      • Exhibit 30: Chart on Distribution Channel - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on Distribution Channel - Market share 2022-2027 (%)
    • 6.2 Comparison by Distribution Channel
      • Exhibit 32: Chart on Comparison by Distribution Channel
      • Exhibit 33: Data Table on Comparison by Distribution Channel
    • 6.3 Hospital pharmacy - Market size and forecast 2022-2027
      • Exhibit 34: Chart on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 35: Data Table on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 36: Chart on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
    • 6.4 Retail pharmacy - Market size and forecast 2022-2027
      • Exhibit 38: Chart on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 39: Data Table on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 40: Chart on Retail pharmacy - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on Retail pharmacy - Year-over-year growth 2022-2027 (%)
    • 6.5 Online pharmacy - Market size and forecast 2022-2027
      • Exhibit 42: Chart on Online pharmacy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 43: Data Table on Online pharmacy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 44: Chart on Online pharmacy - Year-over-year growth 2022-2027 (%)
      • Exhibit 45: Data Table on Online pharmacy - Year-over-year growth 2022-2027 (%)
    • 6.6 Market opportunity by Distribution Channel
      • Exhibit 46: Market opportunity by Distribution Channel ($ million)

    7 Market Segmentation by Indication

    • 7.1 Market segments
      • Exhibit 47: Chart on Indication - Market share 2022-2027 (%)
      • Exhibit 48: Data Table on Indication - Market share 2022-2027 (%)
    • 7.2 Comparison by Indication
      • Exhibit 49: Chart on Comparison by Indication
      • Exhibit 50: Data Table on Comparison by Indication
    • 7.3 Macular degeneration - Market size and forecast 2022-2027
      • Exhibit 51: Chart on Macular degeneration - Market size and forecast 2022-2027 ($ million)
      • Exhibit 52: Data Table on Macular degeneration - Market size and forecast 2022-2027 ($ million)
      • Exhibit 53: Chart on Macular degeneration - Year-over-year growth 2022-2027 (%)
      • Exhibit 54: Data Table on Macular degeneration - Year-over-year growth 2022-2027 (%)
    • 7.4 Diabetic eye disease - Market size and forecast 2022-2027
      • Exhibit 55: Chart on Diabetic eye disease - Market size and forecast 2022-2027 ($ million)
      • Exhibit 56: Data Table on Diabetic eye disease - Market size and forecast 2022-2027 ($ million)
      • Exhibit 57: Chart on Diabetic eye disease - Year-over-year growth 2022-2027 (%)
      • Exhibit 58: Data Table on Diabetic eye disease - Year-over-year growth 2022-2027 (%)
    • 7.5 Others - Market size and forecast 2022-2027
      • Exhibit 59: Chart on Others - Market size and forecast 2022-2027 ($ million)
      • Exhibit 60: Data Table on Others - Market size and forecast 2022-2027 ($ million)
      • Exhibit 61: Chart on Others - Year-over-year growth 2022-2027 (%)
      • Exhibit 62: Data Table on Others - Year-over-year growth 2022-2027 (%)
    • 7.6 Market opportunity by Indication
      • Exhibit 63: Market opportunity by Indication ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 65: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 66: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 67: Chart on Geographic comparison
      • Exhibit 68: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 69: Chart on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 70: Data Table on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 71: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 72: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Europe - Market size and forecast 2022-2027
      • Exhibit 73: Chart on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 74: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 75: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 76: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 77: Chart on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 78: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 79: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 80: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 81: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 82: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 83: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 84: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 85: Chart on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 86: Data Table on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 87: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 88: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 China - Market size and forecast 2022-2027
      • Exhibit 89: Chart on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 90: Data Table on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 91: Chart on China - Year-over-year growth 2022-2027 (%)
      • Exhibit 92: Data Table on China - Year-over-year growth 2022-2027 (%)
    • 9.9 Germany - Market size and forecast 2022-2027
      • Exhibit 93: Chart on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 94: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 95: Chart on Germany - Year-over-year growth 2022-2027 (%)
      • Exhibit 96: Data Table on Germany - Year-over-year growth 2022-2027 (%)
    • 9.10 Spain - Market size and forecast 2022-2027
      • Exhibit 97: Chart on Spain - Market size and forecast 2022-2027 ($ million)
      • Exhibit 98: Data Table on Spain - Market size and forecast 2022-2027 ($ million)
      • Exhibit 99: Chart on Spain - Year-over-year growth 2022-2027 (%)
      • Exhibit 100: Data Table on Spain - Year-over-year growth 2022-2027 (%)
    • 9.11 Canada - Market size and forecast 2022-2027
      • Exhibit 101: Chart on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 102: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 103: Chart on Canada - Year-over-year growth 2022-2027 (%)
      • Exhibit 104: Data Table on Canada - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 105: Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 106: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 107: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 108: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 109: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 110: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 111: Matrix on vendor position and classification
            • 12.3 AbbVie Inc.
              • Exhibit 112: AbbVie Inc. - Overview
              • Exhibit 113: AbbVie Inc. - Product / Service
              • Exhibit 114: AbbVie Inc. - Key news
              • Exhibit 115: AbbVie Inc. - Key offerings
            • 12.4 Alcon Inc.
              • Exhibit 116: Alcon Inc. - Overview
              • Exhibit 117: Alcon Inc. - Business segments
              • Exhibit 118: Alcon Inc. - Key offerings
              • Exhibit 119: Alcon Inc. - Segment focus
            • 12.5 Alimera Sciences Inc.
              • Exhibit 120: Alimera Sciences Inc. - Overview
              • Exhibit 121: Alimera Sciences Inc. - Product / Service
              • Exhibit 122: Alimera Sciences Inc. - Key offerings
            • 12.6 Bausch Health Co Inc.
              • Exhibit 123: Bausch Health Co Inc. - Overview
              • Exhibit 124: Bausch Health Co Inc. - Business segments
              • Exhibit 125: Bausch Health Co Inc. - Key news
              • Exhibit 126: Bausch Health Co Inc. - Key offerings
              • Exhibit 127: Bausch Health Co Inc. - Segment focus
            • 12.7 Bayer AG
              • Exhibit 128: Bayer AG - Overview
              • Exhibit 129: Bayer AG - Business segments
              • Exhibit 130: Bayer AG - Key news
              • Exhibit 131: Bayer AG - Key offerings
              • Exhibit 132: Bayer AG - Segment focus
            • 12.8 Bristol Myers Squibb Co.
              • Exhibit 133: Bristol Myers Squibb Co. - Overview
              • Exhibit 134: Bristol Myers Squibb Co. - Product / Service
              • Exhibit 135: Bristol Myers Squibb Co. - Key news
              • Exhibit 136: Bristol Myers Squibb Co. - Key offerings
            • 12.9 F. Hoffmann La Roche Ltd.
              • Exhibit 137: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 138: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 139: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 140: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 141: F. Hoffmann La Roche Ltd. - Segment focus
            • 12.10 Johnson and Johnson Services Inc.
              • Exhibit 142: Johnson and Johnson Services Inc. - Overview
              • Exhibit 143: Johnson and Johnson Services Inc. - Business segments
              • Exhibit 144: Johnson and Johnson Services Inc. - Key news
              • Exhibit 145: Johnson and Johnson Services Inc. - Key offerings
              • Exhibit 146: Johnson and Johnson Services Inc. - Segment focus
            • 12.11 MeiraGTx Holdings Plc
              • Exhibit 147: MeiraGTx Holdings Plc - Overview
              • Exhibit 148: MeiraGTx Holdings Plc - Product / Service
              • Exhibit 149: MeiraGTx Holdings Plc - Key offerings
            • 12.12 Novartis AG
              • Exhibit 150: Novartis AG - Overview
              • Exhibit 151: Novartis AG - Business segments
              • Exhibit 152: Novartis AG - Key offerings
              • Exhibit 153: Novartis AG - Segment focus
            • 12.13 Ocular Therapeutix Inc.
              • Exhibit 154: Ocular Therapeutix Inc. - Overview
              • Exhibit 155: Ocular Therapeutix Inc. - Product / Service
              • Exhibit 156: Ocular Therapeutix Inc. - Key offerings
            • 12.14 Oxurion NV
              • Exhibit 157: Oxurion NV - Overview
              • Exhibit 158: Oxurion NV - Product / Service
              • Exhibit 159: Oxurion NV - Key offerings
            • 12.15 Pfizer Inc.
              • Exhibit 160: Pfizer Inc. - Overview
              • Exhibit 161: Pfizer Inc. - Product / Service
              • Exhibit 162: Pfizer Inc. - Key news
              • Exhibit 163: Pfizer Inc. - Key offerings
            • 12.16 Regeneron Pharmaceuticals Inc.
              • Exhibit 164: Regeneron Pharmaceuticals Inc. - Overview
              • Exhibit 165: Regeneron Pharmaceuticals Inc. - Product / Service
              • Exhibit 166: Regeneron Pharmaceuticals Inc. - Key offerings
            • 12.17 Sanofi SA
              • Exhibit 167: Sanofi SA - Overview
              • Exhibit 168: Sanofi SA - Business segments
              • Exhibit 169: Sanofi SA - Key news
              • Exhibit 170: Sanofi SA - Key offerings
              • Exhibit 171: Sanofi SA - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 172: Inclusions checklist
                • Exhibit 173: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 174: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 175: Research methodology
                • Exhibit 176: Validation techniques employed for market sizing
                • Exhibit 177: Information sources
              • 13.5 List of abbreviations
                • Exhibit 178: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              retinal drugs market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis